172 related articles for article (PubMed ID: 21403128)
1. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation.
Xiao H; Shi J; Luo Y; Tan Y; He J; Xie W; Zhang L; Wang Y; Liu L; Wu K; Yu X; Cai Z; Lin M; Ye X; Huang H
Blood; 2011 May; 117(19):5257-60. PubMed ID: 21403128
[TBL] [Abstract][Full Text] [Related]
2. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
3. Disease evolution and outcomes in familial AML with germline CEBPA mutations.
Tawana K; Wang J; Renneville A; Bödör C; Hills R; Loveday C; Savic A; Van Delft FW; Treleaven J; Georgiades P; Uglow E; Asou N; Uike N; Debeljak M; Jazbec J; Ancliff P; Gale R; Thomas X; Mialou V; Döhner K; Bullinger L; Mueller B; Pabst T; Stelljes M; Schlegelberger B; Wozniak E; Iqbal S; Okosun J; Araf S; Frank AK; Lauridsen FB; Porse B; Nerlov C; Owen C; Dokal I; Gribben J; Smith M; Preudhomme C; Chelala C; Cavenagh J; Fitzgibbon J
Blood; 2015 Sep; 126(10):1214-23. PubMed ID: 26162409
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
[TBL] [Abstract][Full Text] [Related]
5. Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation.
Spinelli O; Giussani U; Borleri G; Lazzari M; Michelato A; Dotti G; Barbui T; Rambaldi A
Haematologica; 2000 Nov; 85(11):1153-7. PubMed ID: 11064467
[TBL] [Abstract][Full Text] [Related]
6. Germline CEBPA mutations in Korean patients with acute myeloid leukemia.
Kim HS; Han E; Jang W; Kim M; Kim Y; Han K; Kim HJ; Cho B
Leuk Res; 2019 Jan; 76():84-86. PubMed ID: 30563700
[No Abstract] [Full Text] [Related]
7. Familial CEBPA-mutated acute myeloid leukemia.
Tawana K; Rio-Machin A; Preudhomme C; Fitzgibbon J
Semin Hematol; 2017 Apr; 54(2):87-93. PubMed ID: 28637622
[TBL] [Abstract][Full Text] [Related]
8. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
[TBL] [Abstract][Full Text] [Related]
9. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.
Schlenk RF; Taskesen E; van Norden Y; Krauter J; Ganser A; Bullinger L; Gaidzik VI; Paschka P; Corbacioglu A; Göhring G; Kündgen A; Held G; Götze K; Vellenga E; Kuball J; Schanz U; Passweg J; Pabst T; Maertens J; Ossenkoppele GJ; Delwel R; Döhner H; Cornelissen JJ; Döhner K; Löwenberg B
Blood; 2013 Aug; 122(9):1576-82. PubMed ID: 23863898
[TBL] [Abstract][Full Text] [Related]
10. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
[TBL] [Abstract][Full Text] [Related]
11. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
12. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
[TBL] [Abstract][Full Text] [Related]
13. Getting a handle on hereditary CEBPA mutations.
DiNardo CD
Blood; 2015 Sep; 126(10):1156-8. PubMed ID: 26337351
[No Abstract] [Full Text] [Related]
14. [Investigation and clinical analysis of a family with germline CEBPA mutations in acute myeloid leukemia].
Zhang JP; Lin D; Wang SC; Li Y; Chen YM; Wang Y; Wei H; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1008-1012. PubMed ID: 33445848
[No Abstract] [Full Text] [Related]
15. [CEBPA gene mutation analysis in acute myeloid leukemia].
Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
[TBL] [Abstract][Full Text] [Related]
16. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
[TBL] [Abstract][Full Text] [Related]
17. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
Ahmad F; Rajput S; Mandava S; Das BR
Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
[TBL] [Abstract][Full Text] [Related]
18. Hereditary acute myeloid leukemia associated with C-terminal CEBPA germline variants.
Harrigan AM; Trottier AM
Fam Cancer; 2023 Jul; 22(3):331-339. PubMed ID: 36879149
[TBL] [Abstract][Full Text] [Related]
19. CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.
Libura M; Pawełczyk M; Florek I; Matiakowska K; Jaźwiec B; Borg K; Solarska I; Zawada M; Czekalska S; Libura J; Salamanczuk Z; Jakóbczyk M; Mucha B; Duszeńko E; Soszyńska K; Karabin K; Piątkowska-Jakubas B; Całbecka M; Gajkowska-Kulig J; Gadomska G; Kiełbiński M; Ejduk A; Kata D; Grosicki S; Kyrcz-Krzemień S; Warzocha K; Kuliczkowski K; Skotnicki A; Jęrzejczak WW; Haus O
Blood Cells Mol Dis; 2015 Dec; 55(4):284-92. PubMed ID: 26460249
[TBL] [Abstract][Full Text] [Related]
20. Haploidentical
Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
